IDH metabolites induce a BRCAness that can be exploited by PARP inhibitors

Durable responses to avelumab in patients with Merkel cell carcinoma

Atezolizumab in metastatic TNBC: Long-term clinical outcomes and biomarker analyses

Five-year follow-up of nivolumab in NSCLC

Mutations in cancer predisposition genes and risk for subsequent neoplasms

Final overall survival analysis of MONARCH 1

Redefining tamoxifen for breast cancer

Olaparib and temozolomide for relapsed small cell lung cancer

Treatment choices for HER2 amplified colorectal cancer

Final results of the HERACLES trial in HER2-amplified colorectal cancer

Results of SUMMIT: a global phII trial of neratinib in HER2/3 mutant solid tumours

Neratinib in HER2 or HER3 mutant solid tumours